Osiris Therape…
ProfileJobs

Osiris Therapeutics

Suggest Edit
    • Healthbiotechgenetics

    Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its product Grafix is a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns. In addition, the Company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.

    Market capitalization(2017-10-31)
    $172.3 M
    Type
    Public
    HQ
    Columbia, US
    Founded
    1992
    Size (employees)
    211 (est)
    Website
    osiris.com
    Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, US
    Report incorrect company information

    Key People/Management at Osiris Therapeutics

    Linda Chang

    Linda Chang

    Chief Financial Officer
    Jason Keefer

    Jason Keefer

    Interim President & CEO, VP of Marketing

    Osiris Therapeutics Office Locations

    Osiris Therapeutics has an office in Columbia
    Columbia, US (HQ)
    7015 Albert Einstein Drive
    Show all (1)
    Report incorrect company information

    Osiris Therapeutics Financials and Metrics

    Osiris Therapeutics Financials

    USD

    Revenue (Q1, 2018)

    		31.6 m

    Gross profit (Q1, 2018)

    		22.8 m

    Gross profit margin (Q1, 2018), %

    		72%

    Net income (Q1, 2018)

    		(2.3 m)

    EBIT (Q1, 2018)

    		(2.5 m)

    Market capitalization (31-Oct-2017)

    		172.3 m

    Closing share price (31-Oct-2017)

    		4.7

    Cash (31-Mar-2018)

    		3.4 m
    Osiris Therapeutics's current market capitalization is $172.3 m.
    Annual
    USDFY, 2013FY, 2014

    EBIT

    		(2.8 m)1.7 m

    Net Income

    		41.6 m(1.8 m)
    Quarterly
    USDQ1, 2018

    Revenue

    		31.6 m

    Cost of goods sold

    		8.9 m

    Gross profit

    		22.8 m

    Gross profit Margin, %

    		72%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2017

    Cash

    		2.4 m2.2 m3.1 m

    Accounts Receivable

    		15.3 m10 m26.1 m

    Inventories

    		355 k650 k11.3 m

    Current Assets

    		84.1 m95.9 m72.9 m
    Quarterly
    USDQ1, 2018

    Cash

    		3.4 m

    Accounts Receivable

    		26.5 m

    Inventories

    		11 m

    Current Assets

    		73.3 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2017

    Net Income

    		8.8 m

    Depreciation and Amortization

    		587 k940 k688 k

    Inventories

    		(651 k)(9 m)

    Accounts Payable

    		(2.8 m)(57 k)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018

    Net Income

    		(2.3 m)

    Depreciation and Amortization

    		211 k

    Inventories

    		1.7 m2.3 m5.5 m8.8 m11.9 m13.3 m15.8 m

    Accounts Payable

    		4 m8 m9.3 m9.8 m9.2 m9.6 m
    show all
    USDY, 2018

    Financial Leverage

    		2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    HTG Molecular Diagnostics
    Health - Public
    Editas Medicine
    Health - Public
    Poseida Therapeutics
    Health - Private
    Scenic Biotech
    Health - Private
    Compare competitors

    Osiris Therapeutics News and Updates

    April 09, 2018

    Osiris Therapeutics: Regenerated

    Report incorrect company information
    Download PDF